Preparing for patients with high-consequence infectious diseases: Example of a high-level isolation unit.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 26 11 2021
accepted: 14 02 2022
entrez: 3 3 2022
pubmed: 4 3 2022
medline: 12 3 2022
Statut: epublish

Résumé

Patients with high-consequence infectious diseases (HCID) are rare in Western Europe. However, high-level isolation units (HLIU) must always be prepared for patient admission. Case fatality rates of HCID can be reduced by providing optimal intensive care management. We here describe a single centre's preparation, its embedding in the national context and the challenges we faced during the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. Ten team leaders organize monthly whole day trainings for a team of doctors and nurses from the HLIU focusing on intensive care medicine. Impact and relevance of training are assessed by a questionnaire and a perception survey, respectively. Furthermore, yearly exercises with several partner institutions are performed to cover different real-life scenarios. Exercises are evaluated by internal and external observers. Both training sessions and exercises are accompanied by intense feedback. From May 2017 monthly training sessions were held with a two-month and a seven-month break due to the first and second wave of the SARS-CoV-2 pandemic, respectively. Agreement with the statements of the questionnaire was higher after training compared to before training indicating a positive effect of training sessions on competence. Participants rated joint trainings for nurses and doctors at regular intervals as important. Numerous issues with potential for improvement were identified during post processing of exercises. Action plans for their improvement were drafted and as of now mostly implemented. The network of the permanent working group of competence and treatment centres for HCID (Ständiger Arbeitskreis der Kompetenz- und Behandlungszentren für Krankheiten durch hochpathogene Erreger (STAKOB)) at the Robert Koch-Institute (RKI) was strengthened throughout the SARS-CoV-2 pandemic. Adequate preparation for the admission of patients with HCID is challenging. We show that joint regular trainings of doctors and nurses are appreciated and that training sessions may improve perceived skills. We also show that real-life scenario exercises may reveal additional deficits, which cannot be easily disclosed in training sessions. Although the SARS-CoV-2 pandemic interfered with our activities the enhanced cooperation among German HLIU during the pandemic ensured constant readiness for the admission of HCID patients to our or to collaborating HLIU. This is a single centre's experience, which may not be generalized to other centres. However, we believe that our work may address aspects that should be considered when preparing a unit for the admission of patients with HCID. These may then be adapted to the local situations.

Identifiants

pubmed: 35239726
doi: 10.1371/journal.pone.0264644
pii: PONE-D-21-37182
pmc: PMC8893674
doi:

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0264644

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Secur. 2019 Jan/Feb;17(1):69-73
pubmed: 30779609
Lancet. 2015 Apr 11;385(9976):1428-35
pubmed: 25534190
Euro Surveill. 2018 Sep;23(38):
pubmed: 30255836
Euro Surveill. 2017 Sep;22(39):
pubmed: 29019307
N Engl J Med. 2014 Dec 18;371(25):2394-401
pubmed: 25337633
Lancet. 2018 Feb 17;391(10121):700-708
pubmed: 29054555
Euro Surveill. 2017 Sep;22(39):
pubmed: 29019309
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2009 Feb;52(2):214-8
pubmed: 19214459
PLoS One. 2014 Oct 28;9(10):e100401
pubmed: 25350843
Lancet Infect Dis. 2009 Jan;9(1):45-56
pubmed: 19095195
N Engl J Med. 2016 Feb 18;374(7):636-46
pubmed: 26886522
Clin Microbiol Infect. 2019 Apr;21S:e28-e31
pubmed: 24816494
Ann Am Thorac Soc. 2016 May;13(5):600-8
pubmed: 27057583
J Nurs Adm. 2018 Nov;48(11):553-560
pubmed: 33216517
Euro Surveill. 2007 Jun 01;12(6):E5-6
pubmed: 17991402

Auteurs

Frieder Pfäfflin (F)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Miriam Songa Stegemann (MS)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Katrin Moira Heim (KM)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Stephan Achterberg (S)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Ursula Pfitzner (U)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Louise Götze (L)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Lars Oesterhelweg (L)

Institute of Legal Medicine and Forensic Sciences, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Norbert Suttorp (N)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Christian Herzog (C)

Centre for Biological Threats, Strategy and Incident Response, Robert Koch-Institute, Berlin, Germany.

Benjamin Stadtmann (B)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Alexander Uhrig (A)

Department for Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH